![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL
Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado (D.L.C., Z.K., B.R.I., D.R.P.); and Division of Medicinal and Natural Products Chemistry, College of Pharmacy, University of Iowa, Iowa City, Iowa (J.A.D.)
Received for publication
April 15, 2005
Accepted
June 8, 2005.
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
,
-unsaturated aldehyde, including 4-hydroxy-2-nonenal (4-HNE) and 4-oxo-2-nonenal (4-ONE). These aldehydes have a documented ability to disrupt protein function following adduct formation with specific residues. Therefore, to identify 4-HNE-modified proteins in a model of ethanol-induced oxidative stress, a proteomic approach was applied to liver fractions prepared from rats fed a combination high-fat/ethanol diet. The results revealed that essential 90-kDa heat shock protein (Hsp90) was consistently modified by 4-HNE in the alcohol-treated animals. In vitro chaperoning experiments using firefly luciferase as a client protein were then performed to assess the functional effect of 4-HNE modification on purified recombinant human Hsp90, modified with concentrations of this aldehyde ranging from 23 to 450 µM. Modification of Hsp90 with 4-ONE also led to significant inhibition of the chaperone. Because 4-HNE and 4-ONE react selectively with Cys, a thiol-specific mechanism of inhibition was suggested by these data. Therefore, thiol sensitivity was confirmed following treatment of Hsp90 with the specific thiol modifier N-ethylmaleimide, which resulted in more than 99% inactivation of the chaperone by concentrations as low as 6 µM (1:1 M ratio). Finally, tryptic digest of 4-HNE-modified Hsp90 followed by liquid chromatography/tandem mass spectrometry peptide analysis identified Cys 572 as a site for 4-HNE modification. The results presented here thus establish that 4-HNE consistently modifies Hsp90 in a rat model of alcohol-induced oxidative stress and that the chaperoning activity of this protein is subject to dysregulation through thiol modification.
) and is involved in essential physiological processes, including protein trafficking and signal transduction (Bell and Poland, 2000), protein degradation (Goasduff and Cederbaum, 2000), and regulation and stabilization of a wide range of client proteins (Wegele et al., 2004). In humans, Hsp90 exists in either the isoform or the more prominent isoform, which share approximately 85% homology (Hickey et al., 1989). Each isoform consists of an ATPase domain (N-terminal), middle domain, and dimerization domain (C-terminal) (Wegele et al., 2004). Although Hsp90 typically exists as a homodimer, experiments in defined systems have documented a chaperoning activity by self-oligomerization of Hsp90 and client protein binding in a thermally denaturing environment, thus maintaining the substrate protein in a folding-competent form (Yonehara et al., 1996). Refolding of the substrate is accomplished with the addition of Hsp70 along with other essential chaperones and cochaperones such as Hsp60, chaperonin 10, and Hsp-organizing protein (Johnson et al., 1998).
In yeast-expressing nonfunctional Hsp90, it was shown that the absence of this chaperone was lethal (Borkovich et al., 1989). This observation has led to the emergence of Hsp90 as a chemotherapeutic target for the treatment of multiple carcinomas, including breast cancer (Beliakoff and Whitesell, 2004), prostate cancer (Solit et al., 2003), and acute myelogenous leukemia (George et al., 2004). However, although Hsp90 may be a lucrative target for the treatment of cancer, inhibition of Hsp90 in non-neoplastic disorders, such as alcoholic liver disease (ALD), would likely impact cell survival, further complicating the disease.
Oxidative stress, such as that documented to occur during ethanol metabolism, is typically accompanied by the production of electrophilic aldehydes, which are formed following the peroxidation of lipid membranes (Niemela, 1999). Of these compounds, 4-hydroxy-2-nonenal (4-HNE) (Fig. 1A) has been widely studied, and the ability of this aldehyde to disrupt cellular processes through 1,4 Michael addition with Cys, His, and Lys residues, as well as Schiff base formation with primary amines, has been reported (Esterbauer et al., 1991). In addition to 4-HNE, the aldehyde 4-oxo-2-nonenal (4-ONE) is emerging as an especially reactive electrophile (Doorn and Petersen, 2002), likely caused by the ketone group (Fig. 1B), which allows nucleophilic attack at both the second and third carbons, as opposed to 4-HNE, which can undergo nucleophilic attack only at the third carbon.
|
), with a well-established ability to disrupt protein function (Uchida and Stadtman, 1993; Luckey et al., 1999; Alderton et al., 2003). Because of their pathogenic potential, these aldehydes were recently the focus of a proteomic study (Carbone et al., 2004) in which it was found that several crucial proteins were modified by 4-HNE in a rat model of early-stage ALD. The current study represents an extension of the earlier report and documents consistent modification of Hsp90 by 4-HNE in the animals receiving an ethanol-containing diet. Because Hsp90 has an established role in maintaining cell homeostasis (Wegele et al., 2004), disruption of this molecular chaperone would impact multiple cell housekeeping pathways and would likely be detrimental to cell survival. Therefore, further experimentation was conducted to test the hypothesis that lipid aldehyde modification of Hsp90 results in decreased chaperoning efficiency. Specifically, in a system using purified recombinant Hsp90 with heat denatured firefly luciferase as a client protein, inhibition of Hsp90-mediated chaperoning by the Cys-reactive aldehydes 4-HNE and 4-ONE was established. Given the importance of Hsp90 in cellular homeostasis, the results presented here suggest that modification of this protein by lipid aldehydes produced by oxidative stress associated with ALD may contribute to progression of the disease. Collectively, this and the previous report (Carbone et al., 2004) provide further evidence that modification of intracellular proteins by lipid peroxidation products, such as 4-HNE and 4-ONE, may contribute to disease progression.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
; Doorn and Petersen, 2002). Recombinant firefly luciferase and a luciferase assay system were purchased through Promega. Human recombinant Hsp90 was purchased from StressGen Biotechnologies (San Diego, CA).
Animals. All the procedures involving animals were approved by the Institutional Animal Care and Use Committee of the University of Colorado and were performed in accordance with published National Institutes of Health guidelines. Male Harlan (Indianapolis, IN) Sprague-Dawley rats were fed a modified Lieber-Decarli diet documented previously to initiate liver injury consistent with the early stages of ALD (Carbone et al., 2004). On completion of the feeding protocol, plasma alanine aminotransferase (ALT) determination, tissue harvesting, sectioning, staining, and subcellular fractionation were performed as described in a previous report (Little and Petersen, 1983; Carbone et al., 2004). To assess liver histology, whole liver tissue was fixed in 10% (v/v) sodium phosphate-buffered formalin, pH 7.4. Fat, accumulation, and necrosis were estimated in each H&E-stained section by evaluation of four randomly chosen fields. Fat was assessed by estimating the percentage of cells in each field containing microvesicular or macrovesicular fat, with higher scores indicating a higher percentage of cells containing fat: 0 (absent), 1+ (1–25%), 2+ (25–50%), 3+ (50–75%), and 4+ (100%). Necrosis was scored as 0 (absent), 0.5+ (rare), 1+ (scattered necrotic cells), and 2+ (small foci of >10 necrotic cells). Total pathology scores were determined by summing the scores for steatosis and necrosis. The extent of oxidative injury was also evaluated through immunohistochemical detection of aldehyde-protein adducts in tissue sections from the harvested livers (Sampey et al., 2003) using antibodies shown previously to specifically detect 4-HNE sulfhydryl adducts (Hartley et al., 1999).
Two-Dimensional Electrophoresis and In-Gel Digest. Two-dimensional electrophoretic separation of proteins from rat liver mitochondrial fractions, immunodetection of 4-HNE adducts, and spot harvesting were performed as described previously (Shevchenko et al., 1996; Carbone et al., 2004).
In Vitro Hsp90 Modification by 4-HNE, 4-ONE, or N-Ethylmaleimide, and Tryptic Digest. Because the concentration of purified, recombinant Hsp90 varied between lots, pretreatment of the chaperone was performed as a function of molar ratio to preserve the extent to which the protein was modified. Using this approach, human recombinant Hsp90 was incubated in the presence of aldehyde ranging from 0 to approximately 500 µM (5:1, 10:1, or 100:1 aldehyde/protein molar ratio) in 50 mM sodium phosphate, pH 7.4, overnight (approximately 16 h) at 37°C. Treatment with concentrations of N-ethylmaleimide (NEM) ranging from 6 to 60 µM, corresponding to molar ratios ranging from 1:1 to 10:1, were performed similarly. Free aldehyde or NEM was removed before the addition of the client protein (luciferase) using protein desalting columns (Pierce, Rockford, IL), ensuring no carryover of the thiol modifiers to the protection and refolding reactions. This step was taken to prevent inhibition of luciferase or other components of the refolding system by the thiol modifiers. For tryptic digest, following the aldehyde pretreatment (500 µM 4-HNE), Hsp90 was heat denatured at 100°C for 5 min in the presence of 2 mM -mercaptoethanol and cooled on ice. The chaperone was then digested overnight at 37°C in 10% (v/v) acetonitrile, 50 mM ammonium bicarbonate, and 0.3 µg of trypsin.
Mass Spectral Analysis. Peptides (8 µl) from each in-gel digest, or purified Hsp90 that had previously been treated with 4-HNE and subjected to trypsin digest, were analyzed by liquid chromatography/tandem mass spectrometry (LC-MS/MS) as described previously (Carbone et al., 2004). Following in-gel digest, peptides within the mass range of 500 to 1500 Da were subjected to MS/MS analysis, and MS/MS ion search was performed on deconvoluted spectra using MASCOT for protein identification (Perkins et al., 1999). Peptides from tryptic digest of Hsp90 modified by 4-HNE in vitro were identified based on a mass shift of the parent peptide equal to that of 4-HNE (156 Da). Identity of the aldehyde-modified peptide and location of the adduct were determined via MS/MS analysis. Fragment ions were calculated using the MS-Product feature of ProteinProspector version 4.0.5.
Western Blot Analysis. Immunodetection of 4-HNE adducts following electrophoresis and transfer to polyvinylidene difluoride membrane was performed according to procedures published previously (Carbone et al., 2004). Immunodetection of Hsp90 was performed using antibodies purchased from StressGen Biotechnologies, and protein was visualized using GE Healthcare (Piscataway, NJ) STORM 860 imaging system along with the software package ImageQuant version 5.2 (GE Healthcare).
Luciferase Refolding. Recombinant firefly luciferase was diluted to a concentration of 100 nM in 25 mM Tricine, pH 7.8, 8 mM magnesium sulfate, 10% (v/v) glycerol, and 10 mg/ml of bovine serum albumin, and was stored in aliquots at –80°C (Raynes and Guerriero, 1998). Hsp90-mediated chaperoning was measured using an adaptation of procedures published elsewhere (Minami et al., 2001). Briefly, 20 nM luciferase was denatured in the presence of control (i.e., untreated) or 4-HNE-treated Hsp90 by heating the enzyme to 50°C for 5 min. Luciferase refolding was performed by adding 10 µl of the luciferase/Hsp90 mixture to a solution consisting of 50% RRL, 30 mM HEPES, pH 7.0, 50 mM potassium chloride, 2 mM dithiothreitol, 5 mM magnesium chloride, and 1 mM ATP in a final volume of 65 µl. Refolding was allowed to proceed for up to 40 min, at which time 5-µl aliquots were removed from the refolding buffer and added to 100 µl of luciferase assay reagent (Promega) in borosilicate glass tubes. Luminescence was immediately read using a Los Alamos Diagnostics (Los Alamos, NM) 535 luminometer.
Statistical Methods. Statistical analysis was performed using the software package GraphPad Prism version 3.02 (GraphPad Software Inc., San Diego, CA). Plasma ALT, body-to-weight ratio, and body weight were compared using a two-tailed t test. Representative figures showing luciferase refolding were subsampled no fewer than three times and compared by one-way analysis of variance with Bonferroni post test. These representative figures show a consistent trend observed in no fewer than three independent experiments. In all the cases, mean differences between the treated and control (untreated) groups are indicated (*p < 0.05; **p < 0.01; ***p < 0.001).
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
|
; Tsukamoto and Lu, 2001). Thus, the data presented in Tables 1 and 2 show elevated tissue damage in the livers isolated from rats receiving the ethanol-containing diet accompanied by an elevation in protein modification by the lipid peroxidation product 4-HNE (Fig. 2), showing increased lipid peroxidation.
|
|
It is well established that aldehyde modification can dysregulate protein function (Esterbauer et al., 1991). Thus, a proteome-wide scan was used to locate and identify proteins modified by 4-HNE. Two-dimensional electrophoresis of proteins isolated from rat livers followed by immunoblot against 4-HNE-modified proteins has revealed an array of consistently modified targets. Thus, the aldehyde-modified proteins located were identified using in-gel tryptic digest and LC-MS/MS ion search. Figure 3, A and B, presents typical two-dimensional electrophoresis and immunodetection of 4-HNE protein adducts in control (Fig. 3A) or ethanol-fed animals (Fig. 3B), confirming the presence of more severe aldehydic protein modification in animals fed the ethanol-containing diet. Additionally, the location of the chaperone Hsp90 is indicated in Fig. 3B (arrow); however, immunoreactivity of this protein is noticeably absent in protein harvested from animals receiving the control diet. Although several comigrating proteins were also identified along with Hsp90 (Fig. 3B; Table 3), these proteins were not assigned a MASCOT score deemed significant, nor was their location consistent with the actual mass and isoelectric point of the spot (Table 3). However, both mass and isoelectric point are consistent with that which would be expected of Hsp90. Collectively, Fig. 3B and Table 3 suggest that Hsp90 is indeed the prominent protein in the spot harvested from the gel.
|
|
Finally, a previous report by Carbone et al. (2004) showed a slight induction of Hsp72 in the same animals used for the present study. Therefore, to ensure that the elevated immunoreactivity observed in Fig. 3B was not simply the result of Hsp90 induction, hepatocellular concentrations of this chaperone were compared via Western blot analysis between animals receiving the control diet (Fig. 3C, lanes 2–5) and their respective ethanol-fed pairs (Fig. 3C, lanes 6–9), showing no detectable induction of the protein. A recombinant control was loaded in lane 10, which served as a positional control. Therefore, Fig. 3 indicates that the enhanced immunoreactivity by Hsp90 likely represents aldehydic modification of the protein by 4-HNE, which is consistent with the increased immunodetection in tissue sections observed in Fig. 2, B–D.
It has been documented previously (Carbone et al., 2004) that modification of the inducible Hsp72 by thiol-reactive aldehydes such as 4-HNE and 4-ONE results in inactivation of this chaperone. Because Hsp90 plays an important role in many cell processes, a similar approach was taken to assess the effect of 4-HNE on Hsp90-mediated chaperoning of thermally denatured luciferase. Specifically, previous reports have shown the ability of Hsp90 to maintain recombinant firefly luciferase in a folding-competent form throughout coincubation under thermally denaturing conditions (Minami et al., 2001). When cooled and placed in the RRL used here, which contains Hsp/70-kDa heat shock cognate protein and other associated chaperones, the Hsp90-protected luciferase is refolded more efficiently than unprotected luciferase. Following pretreatment of Hsp90 with concentrations of 4-HNE ranging from 23 to 450 µM (5–100-fold molar excess aldehyde), a significant and concentration-dependent inhibition of Hsp90-mediated chaperoning was observed, as presented in Fig. 4. Finally, 4-HNE has a documented ability to inactivate Hsp72 (Carbone et al., 2004); therefore, free aldehyde was removed before coincubation of 4-HNE-adducted Hsp90 with luciferase, thus ensuring that any inhibition of luciferase refolding was caused by modification of Hsp90 and not the effect of 4-HNE on either luciferase or Hsp70-mediated refolding.
|
4-ONE is a recently discovered lipid peroxidation product, with documented thiol reactivity exceeding that of 4-HNE. Therefore, the effects of 4-HNE and 4-ONE on Hsp90 chaperoning were measured. The data presented in Fig. 4 also summarize a side-by-side comparison of inhibition following pretreatment of Hsp90 with 45 µM (10x molar excess aldehyde) 4-HNE or 4-ONE, resulting in a similar extent of protein inactivation. Interestingly, the slight difference in the extent of inhibition by 4-ONE was deemed to be significantly different (p < 0.05) from that following pretreatment of the chaperone with an identical (45 µM or 10x molar excess) concentration of 4-HNE and is likely the result of increased thiol reactivity by 4-ONE (Doorn and Petersen, 2002).
Thus, the increased extent of Hsp90 inactivation by 4-ONE suggests inhibition of this chaperone as a function of Cys modification. This notion was subsequently confirmed through pretreatment of Hsp90 with the Cys modifier NEM (Fig. 5). Specifically, the data in Fig. 5 show that treatment of Hsp90 with concentrations of NEM as low as 6 µM, representing a 1:1 molar ratio between the thiol modifier and the chaperone, almost completely abolished the activity of the Hsp. Higher concentrations were similarly effective at inhibiting Hsp90 chaperoning activity. Again, as with experiments performed with 4-HNE or 4-ONE, excess NEM was removed before coincubation with the client protein (luciferase), ensuring that the observed effect was not caused by NEM interference with luciferase or the RRL.
|
) has suggested a functional role for Cys residues based on the slight reductase activity shown by Hsp90. Therefore, tryptic digest of purified recombinant Hsp90 previously treated with 4-HNE followed by LC-MS/MS peptide analysis was performed, confirming modification of a peptide corresponding to amino acids 568 to 573 (FENLCK; 753.4 Da). A shift in m/z of the parent peptide equal to the mass of 4-HNE (156 Da) is shown by Fig. 6A, and the adduct confirmed through MS/MS of m/z 909.4 (Fig. 6B), in which neutral loss of the adduct reveals the mass of the parent peptide, or m/z 753.4. Finally, the identity of peptide 568 to 573 (FENLCK) and the site of the 4-HNE adduct were confirmed through the appearance of the following fragment ions: y4 (477.3), b4-NH3 (487.2), b4 (504.3), a5-NH3 (562.2), b5-NH3 (590.2), and b5 (607.3). Although sequence coverage of Hsp90 following tryptic digest was incomplete and typically resulted in only 40%, modification of Cys 572 was consistently observed. Interestingly, a previous report had predicted that Cys 572 was among the least reactive of the seven Cys residues possessed by Hsp90 (Nardai et al., 2000). However, the possibility exists that other Cys residues were modified by 4-HNE as well and could not be detected because of loss of the adduct during protein digest and LC-MS/MS procedures or simply because the appropriate peptide could not be identified. Also, despite repeated attempts, because of incomplete digest of Hsp90, the modification of Cys 572 in protein isolated from the ethanol-fed animals could not be confirmed because the limited number of peptides isolated following in-gel digest of the protein did not include this residue. Thus, the spectra in Fig. 6, along with the data presented in Figs. 4, 5, 6, suggest a role for this amino acid in the chaperoning functions of client proteins.
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
). As a logical extension of a previously published proteomic study (Carbone et al., 2004), the present report shows that the lipid peroxidation product 4-HNE consistently modified an essential molecular chaperone, Hsp90, in a rat model of alcohol-induced oxidative liver injury. Because aldehydes such as 4-HNE have a well-established ability to modify proteins and consequently disrupt protein function (Uchida and Stadtman, 1993; Luckey et al., 1999; Alderton et al., 2003), and because Hsp90 is critical to cell survival (Borkovich et al., 1989), it is conceivable that dysregulation of this Hsp could initiate or augment progression of an existing disorder such as ALD. Given the prevalence of alcoholism in the United States (Li, 2004), as well as the dismal outcome associated with later (cirrhotic) stages of the ALD (Stinson et al., 2001), characterizing the effect of the lipid peroxidation product 4-HNE on Hsp90 was the immediate focus of the present report, with the hope of gaining further insight into the molecular mechanisms behind the ALD.
In the studies described here, Hsp90-assisted firefly luciferase refolding was significantly inhibited in an RRL system following modification of Hsp90 with 45 µM 4-ONE (5:1 M ratio), as well as concentrations of 4-HNE ranging from 23 to 450 µM (5:1 to 100:1 aldehyde/protein ratio; Fig. 4). It should be noted that these concentrations were chosen strictly because of the molar ratio between the aldehyde and the chaperone and do not necessarily reflect physiological or pathological concentrations of 4-HNE or 4-ONE. In fact, intracellular concentrations of 4-HNE have been estimated to reach cytosolic concentrations of up to 10 µM (Poli and Schaur, 2000). Unfortunately, because 4-ONE has only recently been recognized as a potentially pathogenic compound, similar estimates regarding intracellular concentrations are lacking. However, although the concentrations used in the experiments presented here exceed estimates for intracellular 4-HNE concentrations, evidence is provided by this report that Hsp90 is indeed modified by 4-HNE under conditions of oxidative stress and that this modification very likely leads to inactivation of the protein.
A previous report that measured the ability of 4-ONE to modify various amino acids showed higher reactivity of this aldehyde toward Cys than that reported for 4-HNE (Doorn and Petersen, 2002). Additionally, a recent report characterizing the effects of both 4-HNE and 4-ONE on the inducible chaperone Hsp72 showed a thiol-specific mechanism of inactivation (Carbone et al., 2004). The data presented in Fig. 4 support the notion that inactivation of Hsp90 is proceeding through a Cys-based mechanism because treatment of the chaperone with 4-ONE resulted in significantly greater inhibition (p < 0.05) than observed by an identical concentration of 4-HNE. Therefore, to test the hypothesis that inactivation of Hsp90 by lipid peroxidation products such as 4-HNE and 4-ONE is a function of Cys modification, the chaperone was treated with the specific thiol modifier NEM. Confirmation of this notion is presented in Fig. 5, showing nearly complete (i.e., >99%) inactivation of Hsp90 following treatment of the protein with concentrations of NEM as low as 6 µM. Because this concentration represented a 1:1 M ratio between the Cys modifier and Hsp90 in the pretreatment, the data also suggest that modification of a single Cys residue results in inactivation of the chaperone.
Reasons behind the extreme potency of NEM compared with either 4-HNE- or 4-ONE-mediated Hsp90 inactivation remain unknown. However, a plausible explanation is that these two lipid peroxidation products are reactive with amino acids other than Cys. Specifically, both aldehydes, which have the highest reactivity for Cys, are capable of modifying His and Lys, and in the case of 4-ONE, Arg as well (Doorn and Petersen, 2002; Oe et al., 2003). Therefore, it is possible that these other amino acids may also serve as targets for aldehyde modification. Attempts to test this possibility were unfortunately hindered by the relative resistance of Hsp90 to tryptic digest, which is required for LC-MS/MS peptide analysis and adduct characterization. Despite sequence coverage typically in the range of 40%, a stable Cys modification by 4-HNE was observed, lending credibility to the claim of thiol modification as the mechanism behind Hsp90 inactivation.
If indeed modification of Cys residues is responsible for inactivation of Hsp90 by the lipid peroxidation products 4-HNE and 4-ONE, as is strongly suggested through differential inhibition by 4-HNE and 4-ONE, inhibition by NEM, and mass spectral identification of Cys modification by 4-HNE, then a mechanism distinct from that observed with the classic Hsp90 inhibitor geldanamycin is likely. This rationale stems from the fact that geldanamycin interacts with Hsp90 in the ATPase (N-terminal) domain (Whitesell et al., 1992). However, because Hsp90 lacks Cys residues in this domain (Yamakazi et al., 1989), modification of the ATPase region by thiol-reactive aldehydes such as 4-HNE is unlikely. Therefore, the formation of 4-HNE adducts is probably occurring in a region other than the ATPase domain of the Hsp, leading to a mechanism of inhibition that is probably distinct from that of geldanamycin.
Although the exact mechanism of Hsp90 inhibition by 4-HNE and 4-ONE remains unknown, the data presented here show susceptibility of this chaperone to inactivation by lipid peroxidation products through a pathway distinct from classic Hsp90 inhibitors. Furthermore, the consistent appearance of 4-HNE-immunoreactive Hsp90 in the livers of rats chronically ingesting alcohol underscores the importance of characterizing the effect of lipid aldehyde modification on this protein in diseases associated with persistent oxidative stress. Potentially, inactivation of Hsp90 by 4-HNE and other Cys-reactive aldehydes may be a result of impaired substrate or chaperone binding, or ATP hydrolysis. As such, elucidation of these possible pathways is the focus of ongoing research.
Lipid peroxidation occurring under conditions of oxidative stress yields a series of reactive aldehyde species, some of which have received considerable attention regarding the disruption of protein function through modification at critical residues (Esterbauer et al., 1989). However, despite the prevalence and apparent pathogenic potential of these aldehydes, a definite link between lipid peroxidation products and disease progression has remained elusive. Both the study presented here and the previous report characterizing the effects of lipid peroxidation products on Hsp72 function represent an extension of a proteome-wide scan for aldehyde-modified proteins in a rat model of early-stage alcoholic liver injury (Carbone et al., 2004). This proteomic study was conducted under the premise of providing further evidence for a link between lipid aldehydes and disease progression. Specifically, it is the general goal of this work to provide evidence that crucial cellular proteins are targets for modification and inactivation by these aldehydes during disease conditions, thus providing a foundation for more complex experiments examining an in vivo effect.
As stated earlier, the present study represents a logical extension of a previously reported proteome-wide scan (Carbone et al., 2004) to identify substrates for 4-HNE modification in the livers of rats receiving a combination high-fat/ethanol diet. This diet has been shown here and elsewhere to induce early-stage ALD (Diehl, 2001; Tsukamoto and Lu, 2001). Among the proteins modified by this aldehyde is the essential heat shock protein Hsp90, which is involved in crucial cell processes, including protein chaperoning, protein degradation, and protein trafficking. The progression of ALD beyond the steatotic (fatty liver) stage includes the appearance of insoluble cytokeratin aggregates, or Mallory bodies, thus suggesting impairment of protein chaperoning or degradation in this disease. Because Hsp90 is involved in these processes and has been shown to be modified and inactivated by the lipid peroxidation product 4-HNE, the contribution to disease progression through impairment of Hsp90 by lipid peroxidation products is a distinct possibility.
|
Footnotes |
|---|
ABBREVIATIONS: Hsp, heat shock protein; ALD, alcoholic liver disease; 4-HNE, 4-hydroxy-2-nonenal; 4-ONE, 4-oxo-2-nonenal; RRL, rabbit reticulocyte lysate; ALT, alanine aminotransferase; NEM, N-ethylmaleimide; LC-MS/MS, liquid chromatography/tandem mass spectrometry; Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine.
Address correspondence to: Dr. Dennis R. Petersen, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Campus Box C238, Denver, CO 80262. E-mail: dennis.petersen{at}uchsc.edu
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Alderton AL, Faustman C, Liebler DC, and Hill DW (2003) Induction of redox instability of bovine myoglobin by adduction with 4-hydroxy-2-nonenal. Biochemistry 42: 4398–4405.[CrossRef][Medline]
Beliakoff J and Whitesell L (2004) Hsp90: an emerging target for breast cancer therapy. Anticancer Drugs 14: 651–662.
Bell DR and Poland A (2000) Binding of aryl hydrocarbon receptor (AhR) to AhR-interacting protein. The role of hsp90. J Biol Chem 275: 36407–36414.
Borkovich KA, Farrelly FW, Finkelstein DB, Taulien J, and Lindquist S (1989) hsp82 is an essential protein that is required in higher concentrations for growth of cells at higher temperatures. Mol Cell Biol 9: 3919–3930.
Carbone DL, Doorn JA, Kiebler Z, Sampey BP, and Petersen DR (2004) Inhibition of Hsp72-mediated protein refolding by 4-hydroxy-2-nonenal. Chem Res Toxicol 17: 1459–1467.[CrossRef][Medline]
Diehl AM (2001) Nonalcoholic fatty liver disease: implications for alcoholic liver disease. Alcohol Clin Exp Res 25: 8S–14S.[Medline]
Doorn JA and Petersen DR (2002) Covalent modification of amino acid nucleophiles by the lipid peroxidation products 4-hydroxy-2-nonenal and 4-oxo-2-nonenal. Chem Res Toxicol 15: 1445–1450.[CrossRef][Medline]
Esterbauer H, Schaur RJ, and Zollner H (1991) Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free Radic Biol Med 11: 81–128.[CrossRef][Medline]
Esterbauer H, Zollner H, and Schaur RJ (1989) Aldehydes formed by lipid peroxidation: mechanisms of formation, occurrence and determination, in Membrane Lipid Oxidation (Vigo-Pelfrey C ed) vol 1, pp 239–268, CRC Press, Boca Raton.
George P, Bali P, Cohen P, Tao J, Guo F, Sigua C, Vishvanath A, Fiskus W, Scuto A, Annavarapu S, et al. (2004) Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human myelogenous leukemia cells with mutant FLT-3. Cancer Res 64: 3645–3652.
Goasduff T and Cederbaum AI (2000) CYP2E1 degradation by in vitro reconstituted systems: role of the molecular chaperone Hsp90. Arch Biochem Biophys 379: 321–330.[CrossRef][Medline]
Hartley DP, Kolaja KL, Reichard J, and Petersen DR (1999) 4-Hydroxynonenal and malondialdehyde hepatic protein adducts in rats treated with carbon tetrachloride: immunochemical detection an lobular localization. Toxicol Appl Pharmacol 161: 23–33.[CrossRef][Medline]
Hickey E, Brandon SE, Smale G, Lloyd D, and Weber LA (1989) Sequence and regulation of a gene encoding a human 89-kilodalton heat shock protein. Mol Cell Biol 9: 2615–2626.
Johnson BD, Schumacher RJ, Ross ED, and Toft DO (1998) Hop modulates hsp70/hsp90 interactions in protein folding. J Biol Chem 273: 3679–3686.
Lai BT, Chin NW, Stanek AE, Keh W, and Lanks KW (1984) Quantitation and intracellular localization of the 85 K heat shock protein by using monoclonal and polyclonal antibodies. Mol Cell Biol 4: 2802–2810.
Li T (2004) Alcohol use disorders and mood disorders: a National Institute on Alcohol Abuse and Alcoholism perspective. Biol Psychiatry 56: 718–720.[Medline]
Little RG and Petersen DR (1983) Subcellular distribution and kinetic parameters of HS mouse liver aldehyde dehydrogenase. Comp Biochem Physiol 74c: 271–c279.[CrossRef]
Luckey SW, Tjalkens RB, and Petersen DR (1999) Mechanism of inhibition of rat liver class 2 ALDH by 4-hydroxynonenal. Adv Exp Med Biol 463: 71–77.[Medline]
Minami M, Nakamura M, Emori Y, and Minami Y (2001) Both the N- and C-terminal chaperone sites of Hsp90 participate in protein refolding. Eur J Biochem 268: 2520–2524.[Medline]
Mitchell DY and Petersen DR (1991) Inhibition of rat hepatic mitochondrial aldehyde dehydrogenase-mediated acetaldehyde oxidation by trans-4-hydroxy-2-nonenal. Hepatology 13: 728–734.[CrossRef][Medline]
Nardai G, Sass B, Eber J, Orosz G, and Csermely P (2000) Reactive cysteines of the 90-kDa heat shock protein, Hsp90. Arch Biochem Biophys 384: 59–67.[CrossRef][Medline]
Niemela O (1999) Aldehyde-protein adducts in the liver as a result of ethanol-induced oxidative stress. Front Biosci 4: d506–513.
Oe T, Lee SH, Silva Elipe MV, Arison BH, and Blair IA (2003) A novel lipid hydroperoxide-derived modification to arginine. Chem Res Toxicol 16: 1598–1605.[CrossRef][Medline]
Perkins DN, Pappin DJ, Creasy DM, and Cottrell JS (1999) Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20: 3551–3567.[CrossRef][Medline]
Poli G and Schaur RJ (2000) 4-Hydroxynonenal in the pathomechanisms of oxidative stress. IUBMB Life 50: 315–321.[CrossRef][Medline]
Raynes DA and Guerriero V Jr (1998) Inhibition of Hsp70 ATPase activity and protein renaturation by a novel Hsp70-binding protein. J Biol Chem 273: 32883–32888.
Sampey BP, Korourian S, Ronis MJ, Badger TM, and Petersen DR (2003) Immunochemical characterization of hepatic malondialdehyde and 4-hydroxynonenanl modified proteins during early stages of ethanol-induced liver injury. Alcohol Clin Exp Res 27: 1015–1023.[Medline]
Shevchenko A, Wilm M, Vorm O, and Mann M (1996) Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 68: 850–858.[Medline]
Solit DB, Scher HI, and Rosen N (2003) Hsp90 as a therapeutic target in prostate cancer. Semin Oncol 5: 709–716.
Stinson F, Grant BF, and Dufour MC (2001) The critical dimension of ethnicity in liver cirrhosis mortality statistics. Alcohol Clin Exp Res 25: 1181–1187.[CrossRef][Medline]
Tsukamoto H and Lu S (2001) Current concepts in the pathogenesis of alcoholic liver injury. FASEB J 15: 1335–1349.
Uchida K and Stadtman ER (1993) Covalent attachment of 4-hydroxynonenal to glyceraldehyde-3-phosphate dehydrogenase: a possible involvement of intra- and intermolecular cross-linking reaction. J Biol Chem 268: 6388–6393.
Wegele H, Muller L, and Buchner J (2004) Hsp70 and Hsp90-a relay team for protein refolding. Rev Physiol Biochem Pharmacol 151: 1–44.[CrossRef][Medline]
Whitesell L, Shifrin SD, Schwab G, and Neckers LM (1992) Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition. Cancer Res 52: 1721–1728.
Yamazaki M, Akaogi K, Miwa T, Imai T, Soeda E, and Yokoyama K (1989) Nucleotide sequence of a full-length cDNA for 90 kDa heat-shock protein from human peripheral lymphocytes. Nucleic Acids Res 17: 7108.
Yonehara M, Minami Y, Kawata Y, Nagai J, and Yahara I (1996) Heat-induced chaperone activity of HSP90. J Biol Chem 271: 2641–2645.
This article has been cited by other articles:
|
|
 |
|
  S. G. Codreanu, B. Zhang, S. M. Sobecki, D. D. Billheimer, and D. C. Liebler Global Analysis of Protein Damage by the Lipid Electrophile 4-Hydroxy-2-nonenal Mol. Cell. Proteomics, April 1, 2009; 8(4): 670 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Grimsrud, H. Xie, T. J. Griffin, and D. A. Bernlohr Oxidative Stress and Covalent Modification of Protein with Bioactive Aldehydes J. Biol. Chem., August 8, 2008; 283(32): 21837 - 21841. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Trott, J. D. West, L. Klaic, S. D. Westerheide, R. B. Silverman, R. I. Morimoto, and K. A. Morano Activation of Heat Shock and Antioxidant Responses by the Natural Product Celastrol: Transcriptional Signatures of a Thiol-targeted Molecule Mol. Biol. Cell, March 1, 2008; 19(3): 1104 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Winger, N. L. Taylor, J. L. Heazlewood, D. A. Day, and A. H. Millar The Cytotoxic Lipid Peroxidation Product 4-Hydroxy-2-nonenal Covalently Modifies a Selective Range of Proteins Linked to Respiratory Function in Plant Mitochondria J. Biol. Chem., December 28, 2007; 282(52): 37436 - 37447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Jacobs and L. J. Marnett Heat Shock Factor 1 Attenuates 4-Hydroxynonenal-mediated Apoptosis: CRITICAL ROLE FOR HEAT SHOCK PROTEIN 70 INDUCTION AND STABILIZATION OF Bcl-XL J. Biol. Chem., November 16, 2007; 282(46): 33412 - 33420. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Whitsett, M. J. Picklo Sr, and J. Vasquez-Vivar 4-Hydroxy-2-Nonenal Increases Superoxide Anion Radical in Endothelial Cells via Stimulated GTP Cyclohydrolase Proteasomal Degradation Arterioscler Thromb Vasc Biol, November 1, 2007; 27(11): 2340 - 2347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Grimsrud, M. J. Picklo Sr., T. J. Griffin, and D. A. Bernlohr Carbonylation of Adipose Proteins in Obesity and Insulin Resistance: Identification of Adipocyte Fatty Acid-binding Protein as a Cellular Target of 4-Hydroxynonenal Mol. Cell. Proteomics, April 1, 2007; 6(4): 624 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. P. Sampey, D. L. Carbone, J. A. Doorn, D. A. Drechsel, and D. R. Petersen 4-Hydroxy-2-nonenal Adduction of Extracellular Signal-Regulated Kinase (Erk) and the Inhibition of Hepatocyte Erk-Est-Like Protein-1-Activating Protein-1 Signal Transduction Mol. Pharmacol., March 1, 2007; 71(3): 871 - 883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. Sampey, B. J. Stewart, and D. R. Petersen Ethanol-induced Modulation of Hepatocellular Extracellular Signal-regulated Kinase-1/2 Activity via 4-Hydroxynonenal J. Biol. Chem., January 19, 2007; 282(3): 1925 - 1937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yan and B. F. Hales Depletion of Glutathione Induces 4-Hydroxynonenal Protein Adducts and Hydroxyurea Teratogenicity in the Organogenesis Stage Mouse Embryo J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 613 - 621. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
